Please Wait...

Key Cardiovascular Mergers and Acquisitions

With over 25 years of experience in Cardiac Safety monitoring services, Bioclinica is a recognized global leader in providing comprehensive services with unrivalled scientific and technical leadership.  Over the last decade, Bioclinica has grown organically and through strategic acquisitions to enhance and strengthen its cardiac safety expertise, resources and offerings for clinical trial sponsors.

In 2004, Bioclinica (formerly Bio-Imaging Technologies) acquired Heartcore BV, a global provider of centralized cardiovascular imaging analysis specializing in various quantitative image analysis services. In 2013, Bioclinica merged with Core Lab Partners, adding renowned scientific expertise from Medifacts to its cardiovascular team, bolstering its centralized cardiovascular services portfolio and expanding its presence in Asia.  Most recently, in 2014, Bioclinica merged with SYNARC, supplementing an already strong cardiac safety program with additional scientific expertise and operations in the area of Echocardiography and cardiovascular imaging.

Bioclinica continues to strengthen its cardiovascular offerings, providing sponsors with world-class expertise, operations and technology to design, manage, and analyze cardiac safety data in support of new treatments.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Our Medical Imaging team is in the spotlight for a job well done! https://t.co/fkmt0zvPhf https://t.co/D7YMTeiSd3
bioclinica (Yesterday)
RT @melfass: "What this agreement means is that we can allocate scarce resources to areas of higher risk" @US_FDA on MRA with @EMA_News at…
bioclinica (2 days ago)
RT @DrugInfoAssn: What has been the biggest takeway for your organization so far? Tweet @ us using #DIA2017
bioclinica (4 days ago)
"Q" on #RBM & Total Quality Mgmt? @Kristin_Mauri has "A" @DrugInfoAssn #DIA2017 https://t.co/MqCxkmAfa0
bioclinica (4 days ago)
Kristen Mauri shows the @DIA audience the value of risk based monitoring https://t.co/ssJCfc9gQ5
bioclinica (4 days ago)
Innovation Theater Kristin Mauri of @bioclinica presenting on RBM & TQM @DrugInfoAssn #DIA2017 https://t.co/zsGroQcpiU
bioclinica (4 days ago)

Latest Blogs: